

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:


Box AF
Assistant Commissioner for Patents
Washington, D.C. 20231

On October 16, 2002

TOWNSEND and TOWNSEND and CREW LLP

By: Debra Ann DeBello

Debra Ann DeBello



Attorney Docket No.: 016930-000811US
Client Reference: 3013B

PATENT

RECEIVED

OCT 30 2002

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Heidrun Engler et al.

Application No.: 08/889,355

Filed: July 8, 1997

For: COMPOSITIONS AND METHODS
FOR THERAPEUTIC USE

Examiner: Michael C. Wilson

AMENDMENT UNDER 37 CFR 1.116
EXPEDITED PROCEDURE EXAMINING
GROUP 1633

Box AF

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Final Office Action mailed April 23, 2002, please amend this application as follows. As the following amendments place the application in condition for allowance, Applicants respectfully request they be entered.

IN THE ABSTRACT:

Please cancel the present abstract, and substitute in lieu therefore the following:

--The present invention is directed to compositions and methods of treating cancer by gene therapy using a therapeutic gene formulated in a buffer comprising a delivery-enhancing agent. The delivery-enhancing agents of the invention can be used to formulate therapeutic or diagnostic agents, such as proteins, nucleic acids, antisense RNA, small molecules, etc., for